Based on our previous results indicating that METTL1 induces cell cycle arrest by promoting GADD45A and RB1 translation in BC, we assessed whether targeting METTL1 could enhance treatment efficacy when combined with abemaciclib, a dual CDK4/6 inhibitor approved for BC treatment. Here, RB1 is linked to breast cancer.